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Abstract
Objective: To utilize differential gene expression of candidate markers to discriminate
benign APCs (APCs) from malignant and mixed cell APCs.
Background Data: Considerable controversy exists in regard to the appropriate surgical
management of APCs since standard clinical and immunohistochemical methods cannot
reliably determine whether an APC is indolent or aggressive. We have identified five
differentially expressed genes: nucleosome assembly protein 1-like 1 [NAP1L1];
melanoma antigen D2 [MAGE-D2]; metastasis-associated protein 1 [MTA1]; NAcht
Leucine-rich-repeat Protein 1 [NALP1] and Chromogranin A [CgA] that define gut
neuroendocrine (NE) Enterochromaffin (EC) cell behavior. We hypothesized that APC
(APC) malignancy, also derived from EC cells, could be defined by using quantitative
reverse transcriptase-polymerase chain reaction (QRT-PCR) and immunohistochemical
approaches that evaluate potential marker genes.
Methods: Total RNA was isolated using TRIzol reagent from 42 appendiceal samples
including APCs identified at exploration for appendicitis (no evidence of metastasis;
n=16), appendicitis specimens (n=11), malignant appendiceal tumors (>1.5cm, evidence
of metastatic invasion; n=7) and mixed (goblet) cell appendiceal (GBC) adenocarcinoids
(n=3), normal appendiceal tissue (n=5), and five colorectal cancers. Gene expression
(CgA, NAP1L1, MAGE-D2, MTA1 and NALP1) was examined by Q-RT PCR (Applied
Biosystems) and quantified against GAPDH.
Results: CgA message was elevated (>1000-fold, p<0.05) in all tumor types. NAP1L1
was elevated (>10-fold, p<0.03) in both malignant and GBC adenocarcinoids compared
to normal and incidental lesions (p<0.006). MAGE-D2 and MTA1 message were
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significantly elevated (>10-fold, p<0.01) in the malignant and GBC adenocarcinoid
tumors but not in the appendicitis-associated carcinoids or normal mucosa. The apoptotic
marker, NALP1, was over-expressed (>50-fold, p<0.05) in the appendicitis-associated
and malignant APCs, but was significantly decreased (>10-fold, p<0.05) in GBC
adenocarcinoids. Elevated CgA levels indicative of a carcinoid tumor were identified in
one acute appendicitis sample with no histological evidence of a tumor.
Conclusions: These data demonstrate that malignant APCs and GBC adenocarcinoids
have elevated expression of NAP1L1 (mitotic regulation), MAGE-D2 (adhesion), and
MTA1 (estrogen antagonism) compared to APCs identified at appendicitis. This, and the
differences in NALP1 (apoptosis) gene expression (decreased in GBC adenocarcinoids),
provides a series of molecular signatures that differentiate carcinoids of the appendix.
CgA identified all appendiceal tumors as well as covert lesions, which may be more
prevalent than previously recognized. The molecular delineation of malignant
appendiceal tumor potential provides a scientific basis to define the appropriate surgical
management as opposed to morphological assessment alone.
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1. Introduction
Although generally regarded as an insignificant organ, the appendix at the turn of the 19th
century was a source of considerable vexation to clinicians since the diagnosis of
appendicitis was often difficult and outcome commonly associated with considerable
morbidity and mortality.1 It is of interest that a century later, although the problem of
appendicitis has dramatically receded in the pantheon of medical problems, the
pathological delineation and management of appendiceal tumors, particularly carcinoids
remains an area of confusion and difficulty.2-4 The histology of the tumor is often
equivocal, the identification of microscopic spread often difficult to identify if infection
is present, and management decisions are often made on an empiric or purely judgmental
basis. This investigation seeks to identify a molecular profile that can define appendiceal
malignancy and be utilized to provide a basis for the development of rational surgical and
oncological management.
1. a. Evolution of Understanding
Carcinoid tumors are rare, frequently indolent neoplasms that, although clinically welldefined, are regarded as exotic and are consequently often unrecognized. Although little
is known of the men who are credited with the initial description of its distinct histology
and cell type, even less is known of the pathobiology of the lesion. Because these lesions
exhibit a high degree of morphologic and biologic heterogeneity, there is a lack of clarity
regarding their individual characteristics. A more generic term, NE tumor (NET) has
been introduced to replace the term carcinoid and such lesions are currently referred to as
gastroenteropancreatic (GEP) NETs (GEP-NETs).

This notwithstanding, the

classification still requires further refinement because a substantial group of NETs are of
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identifiable malignant potential and represent an indistinct biologic group whose behavior
cannot be accurately predicted. This reflects the fact that traditional morphologic criteria
of neoplasia have limited applicability. Molecular characterization (as yet lacking) is
required to refine and further differentiate GEP-NETs.5
1. b. Early Observations
The earliest recorded descriptions of what were most likely carcinoid tumors as we know
them today came in the second half of the nineteenth century. T. Langhans (1839-1915),
O. Lubarsch (1860-1933), and W. B. Ransom (1860-1909) described unusual tumors in
the small bowel but each failed to adequately investigate these novel entities [Figure 1].

Figure 1. Historical evolution of understanding of carcinoid tumors
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In 1867, T. Langhans described a firm, mushroom-shaped submucosal tumor
projecting into the lumen of the intestine without evidence of peritumoral invasion.6
Histologically, the tumor resembled poorly differentiated glandular tissue arranged in
‘nests’ with a rich, thick fibrous stroma. Thereafter in 1888, Lubarsch reported the postmortem identification of multiple ileal tumors with microscopic evidence of low-grade
penetration into the muscularis circularis as well as hyperplasia of the adjacent
muscularis mucosae.7 Commenting upon the unique characteristics of these tumors,
Lubarsch resisted classifying them as carcinomas.
Two years later, W.B. Ransom provided the first detailed descriptions of the
classical symptomatology of carcinoid syndrome – wheezing and diarrhea - in a patient
with an ileal carcinoid tumor and hepatic metastasis. Aside from histological similarities
to carcinomas, Ransom furthermore noted that carcinoid tumors “may remain undetected
for a long time…[and] demonstrate very slight, local malignancy or tendency to infiltrate
or destroy their surrounding tissues”.8 In an autopsy report of 1895, A. Notthafft
documented three submucosal tumors of the upper jejunum that he described as
“beginning carcinomas”.
1. c. Karzinoide and Oberndorfer
Despite these early descriptions, the definition of carcinoids as neoplasms distinct from
carcinoma had still not been established. This responsibility fell to Siegfried Oberndorfer
(1876-1944). During his tenure at the Pathological Institute of the University of Munich,
Oberndorfer noted in 1907 that these lesions were distinct clinical entities and named
them “karzinoide” (“carcinoma-like”), emphasizing in particular their benign features.
These observations were first presented at the German Pathological Society meeting in
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Dresden in September 1907 and in December of the same year, published his
groundbreaking report “Carcinoid Tumors of the Small Intestine” in the Frankfurt
Journal of Pathology.9
Oberndorfer described their distinct characteristics: “they are mostly small and
multiple, tend to be surrounded by undifferentiated tissues, have the potential to become
invasive, do not metastasize, and grow extremely slowly and are, therefore, of a harmless
nature”.9 The tumors consisted of small polymorphic cells with prominent nuclei and
scant cytoplasm arranged in nests surrounded by dense, fibrous connective tissue
composed of surrounding stroma with epithelial vascular growth adjacent to the tumor.
Since the tumors appeared to have unique clinical characteristics distinguishable from
those evident in carcinomas, Oberndorfer labeled them as “carcinoid-like” or
“karzinoide”.9
Although Oberndorfer’s early contributions to the understanding of the biology of
carcinoid tumors were farsighted, the characterization of these lesions as benign
subsequently proved to be incorrect. Twenty-two years after first describing the tumor,
Oberndorfer elaborated his further experience with thirty-six appendiceal and small
intestinal carcinoids, amending the initial characterization of the benign behavior and
confirming the possibility that “karzinoide” might exhibit malignant features and indeed
metastasize.10
Although the enterochromaffin cell, the carcinoid cell of origin, had been
identified as early as 1897 by N. Kulchitsky (1856-1925), it was not until 1953 that F.
Lembeck (1922–) established that such cells synthesized and secreted serotonin—a
potent bioactive amine. Thereafter the clinical effects of serotonin, including “flushing,”
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were recognized as was the associated relationship of carcinoid heart disease (Biörck in
1952) and fibrosis (Moertel in 1961).11
The recognition of carcinoids as endocrine-related tumors was first outlined by
Gosset and Masson in 1914.12 In 1963, Williams and Sandler classified carcinoids
according to their embryologic site of origin as foregut carcinoids (respiratory tract,
stomach, duodenum, biliary system, and pancreas), midgut carcinoids (small intestine,
appendix, cecum, and proximal colon), and hindgut carcinoids (distal colon and
rectum).13 This classification was the first to emphasize clinicopathologic differences
between the tumor groups composing the gastroenteropancreatic NE tumors (GEP-NETs)
but never achieved general acceptance in routine diagnostic practice because it proved
too imprecise to distinguish between the different biologically relevant GEP-NET entities.
1. d. WHO Classification
The first WHO classification of endocrine tumors (1980) applied the term carcinoid to
most NETs, exempting the endocrine tumors of the pancreas and thyroid, paragangliomas,
small-cell lung carcinomas, and Merkel cell tumors of the skin. Carcinoids were divided
into enterochromaffin (EC) cells, gastrin (G) cells, and an unspecified category. This,
however, has led to misunderstandings between pathologists and clinicians because the
former applied the term carcinoid to all tumors with NE features, whereas the clinicians
used the term carcinoid in reference to a serotonin-producing tumor exhibiting the now
ubiquitously recognized carcinoid syndrome. A further issue was the growing awareness
of the heterogeneity of such tumors, and it was no longer possible to equate a gastric with
an ileal or rectal carcinoid.
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The neoplasms of NE origin that are recognized by the most recent WHO
classification (2000) consist of pure endocrine tumors, mixed endocrine-exocrine tumors
and tumor-like lesions. For pure endocrine tumors, a uniform scheme of classification is
applied for all anatomical sites, identifying three categories: (1) well-differentiated
endocrine tumors with benign or uncertain behavior at the time of diagnosis; (2) welldifferentiated endocrine carcinomas with low-grade malignant behavior, and (3) poorly
differentiated endocrine carcinomas, with high-grade malignant behavior.14 However, to
preclude confusion, the term carcinoid was not completely abandoned, but is used
synonymously with the term “well-differentiated NE tumor”. The term “malignant
carcinoid” is used synonymously with the term well-differentiated NE carcinoma.
Overall, the objective of these multiple revisions was to provide a prognostically
relevant classification system that assessed tumors according to size, proliferative
activity, angioinvasion, organ invasion, metastases, hormone activity, and clinical
syndromes in order to establish a rational basis for predicting prognosis.15
The elucidation of the pathobiology of NETs, however, is hampered by the lack
of scientific tools that define their mechanisms of secretion, proliferation, and metastasis.
Molecular biologic techniques and genetic analysis may facilitate the delineation of the
molecular pathology of NETs and provide novel insights into their cellular mechanisms.16
The most recent assessment of the molecular basis of tumorigenesis of GEPNETs noted multiple differences in chromosomal aberrations and gene expression
patterns between gastrointestinal neuroendocrine and pancreatic endocrine tumors, with a
few areas of overlap in the accumulation of genetic aberrations. These data suggest that
the recent WHO classification of GEP-NETs may require updating.5
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2. Pathology
Carcinoid tumors are usually classified by their embryonic gut origin, and the ubiquitous,
yet inconsistently defined, classification of “typical” vs. “atypical” carcinoids has become
prevalent within the literature, usually in reference to their degree of differentiation.
“Typical” carcinoids, by definition, are tumors with NE differentiation and classical
histologic architecture of trabecular, insular, or ribbon-like cell clusters, with no or
minimal cellular pleomorphism and sparse mitoses.17 “Atypical”carcinoids, however,
refer to aggressive forms of poorly differentiated carcinoid tumors with increased mitotic
activity and the absence or limited extent of necrosis.18
As mentioned above, the term carcinoid is no longer adequate to cover the entire
morphologic and biologic spectrum of neoplasms of the disseminated NE cell system. In
the last two decades, knowledge of the cellular origins and biologic behavior of GEPNETs has increased greatly, due to advances in clinical and morphologic diagnostics. As
a result, a more refined view of the classification and treatment of GEP-NETs has
developed. This supports the need to retire the archaic concept of “carcinoid.”
Classification based on embryological origin (foregut, midgut, and hindgut) is an
outdated but somewhat useful distinction because the features of carcinoid tumors
derived

from

each

respective

location

differ

clinically,

histologically,

and

immunochemically. Thus, foregut and hindgut carcinoids are typically argentaffin
negative, contrary to midgut lesions that are argentaffin positive.19 More recently,
sophisticated modern methods of analysis have fostered the development of precise
classification systems that can discern the motley assortment of peptides and amines
present in carcinoid tumors. Current estimates indicate the identification of as many as 40
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different secretory products in the different varieties of carcinoid.20 The diagnosis of
carcinoid tumors is also supported by ultrastructural findings of intracytoplasmic
electron-dense secretory granules and by immunoreactivity with antibodies to
chromogranin A (CgA).21
2. a. GEP-NET Histology
Phenotypically, the cells of the GEP-NETs may be considered as part of the disseminated
NE cell system, first referred to as “Helle Zellen” (clear cells) and subsequently defined
by Pearse as “APUD cells.”22 These cells are scattered throughout the GI mucosa or in
the pancreas where they form aggregates as described by Langerhans.22 The term “NE”
reflects the phenotypic relationship to neural cells, more specifically pertainining to the
expression of certain common proteins, including neuron-specific enolase (NSE),
synaptophysin, and CgA. These proteins have utility as general markers in the
morphologic diagnosis of GEP-NETs because, for the most part, they are independent of
cell-specific hormone production. More specific markers of the normal and neoplastic NE
cells are the bioactive products (hormones) of the GEP system. Although at least 12
different types of endocrine cells are currently recognized, less than half of the known
hormones are expressed in GEP-NETs.
In addition, it is of interest that the organ in which a particular hormone producing
tumor originates appears to confer biologic and clinical significance in determining
outcome. Thus, duodenal gastrinomas exhibit a far less aggressive behavior pattern than
pancreatic tumors derived from the same cell type (G cell).23, 24
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2. b. Tumor differentiation
To facilitate more accurate delineation of malignancy of neuroendocrine lesions and
hence establish more objective criteria of prognostication, the most recent WHO
classification placed particular emphasis on tumor proliferative activity.25
2. b. i. Well-differentiated tumors
Well-differentiated lesions by definition widely and diffusely express all general markers
of NE differentiation (CgA, synaptophysin, NSE) and may be associated with specific
hormonal syndromes (carcinoid syndrome, Zollinger-Ellison).14 Tumors composed of
ECL cells are found only in the stomach, insulin cell tumors in the pancreas and gastrinproducing cell tumors are solely observed in tissues where normal gastrin-producing cell
is present during the adult or embryonic life (antrum, upper intestine and pancreas).14 EC
cell tumors are observed throughout the gut and the pancreas, but are most common in
the ileum and appendix. Well-differentiated tumors may be of a tentative grade 1
histology characterized by a variable structure, either with solid islet, pseudoglandular,
trabecular or mixed patterns, with low atypia and rare mitoses.26 Tentative grade 2
histology may be characterized by a more solid structure with focal spotty necrosis and
by more moderate atypia and focal mitoses.
The latter more aggressive tumor features prompted the search for
histopathological criteria of malignancy. Some of them refer to the classical tumor
staging system consisting of tumor size, wall invasion or invasion of surrounding tissues,
angioinvasion or perineural space invasion. Other variables pertain to the presence of
atypia, mitotic index, Ki67 index, p53 overexpression and the ploidy status.
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2. b. ii. Poorly-differentiated tumors
Poorly-differentiated endocrine tumors do not express specific cell types, are mostly
composed of protoendocrine cells of small to intermediate size, and are not associated
with hyperfunctional syndromes.14 These lesions display severe grade 3 histology with a
prevalent solid structure, abundant central necrosis, severe cytologic atypia with frequent
atypical mitoses high Ki67 proliferation index and frequent p53 abnormalities.
Chromogranin A is normally absent or focally expressed, while synaptophysin and NSE
are strongly and diffusely expressed.
2. c. Appendiceal carcinoid histology
Appendiceal epithelium is composed of colonic type mucin-secreting cells, diffuse NE
cells of the crypts, and Paneth cells, which are functionally similar to neutrophils and
provide host defense against microbes in the intestine.27 In addition, a population of
subepithelial NE cells located in the lamina propria has also been described.
The initial histologic identification of APCs came in 1928 when Masson
described the subepithelial “Kultschitzky” cells as the origin of APC tumors and
demonstrated that these cells exhibit both endocrine and neural characteristics.28 Unlike
epithelial NE cells, which give rise to carcinoids in other locations, and which are
uniformly distributed along the appendix, the subepithelial NE cells are much more
numerous at the tip of the organ.29 A subsequent study by Shaw confirmed the
neuroectodermal origin of APCs and noted the preponderance of subepithelial NE cells
near the tip.30 This distribution is consistent with the observation that 70%–80% of APCs
occur at the tip, 5%–20% in the body, and only 7%–8% at the base of the organ.30 Tumor
location is of particular importance, since lesions that arise near the base of the appendix
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are more likely to

present symptomatically, either as obstructive appendicitis or

mucocele.31 In addition, while the density of epithelial NE cells remains stable, the
subepithelial NE cells vary throughout their lifespan. Their density is low in infants,
increases with age to a peak around the fourth decade, and thereafter slowly declines in
the elderly.14
2. d. Histologic subtypes of appendiceal carcinoids
Although APCs are frequently considered a very homogeneous pathologic entity, their
characteristics and behavior vary widely when individual histologic subtypes are
considered. Appendiceal adenocarcinomas possess an identical phenotype to that of
colonic tumors, whereas the “conventional” carcinoid tumors of the appendix exhibit an
exclusively NE phenotype.
Appendiceal tumors exhibiting both NE differentiation and mucin production
and/or glandular differentiation are rare and are regarded as “variants” of the “true”
APC.32 Such lesions have previously been variously designated as adenocarcinoid, GBC
carcinomas (GBC), and mixed adenocarcinoma-carcinoid. In the latter instance, the
distinct signet ring cell features have occasionally led to the diagnosis of poorly
differentiated adenocarcinoma.4, 33
The term goblet-cell carcinoid was introduced in 1974 for tumors of the appendix
exhibiting histological features which differ from both ordinary carcinoid and
adenocarcinoma.34 The principal cell type was described as closely resembling the normal
GBC of the epithelium of the intestinal tract, with Panetta’s and argentaffin cells being
present in considerable numbers. Initially these tumors were suspected of being lowgrade malignant tumors exhibiting some potential for recurrence and metastases,
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adequately ‘cured’ by appendectomy.34
The term ‘adenocarcinoid’ was coined in 1978, and despite abundant mucin
production and goblet-cell arrangement, a closer relationship to carcinoid than to
adenocarcinoma was postulated.35 Size was not supposed to be a sufficient prognostic
factor, but neoplasms generally confined to the muscular is propria never exhibited
metastases.29 Consequently, appendectomy was seen as adequate treatment of those
‘adenocarcinoids’ exhibiting no further signs of malignancy. However, in a later series
five patients with diffuse appendiceal involvement all developed intra-abdominal
metastases.36 As a result of this experience, hemicolectomy was recommended for
invasive lesions.37 More extensive surgery may also be warranted for the removal of
potentially positive appendiceal margins, which are generally present in the diffuse type,
or to remove early lymphatic spread, which is reported in 12.5% of patients.38
Recommendation for the more aggressive approach was adopted by a greater part of the
surgical community, which is why approximately 45% of goblet-cell carcinoids were
treated by right hemicolectomy.29 In accordance to the 2002 guidelines of the German
Cancer Society, GBC tumors are now categorized as low-malignant carcinomas of the
appendix.29
It remains a matter of controversy whether GBCs should be considered
adenocarcinomas or as part of the carcinoid tumor spectrum.16 They appear to arise from
subepithelial lamina propria without association with intraepithelial NE cell hyperplasia
or dysplasia of the appendiceal crypt epithelium. Because both the clinical and the
pathologic features of the GBC carcinoid are sufficiently distinctive, they are probably
best recognized as a separate entity.
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3. Epidemiology
Approximately 75% of carcinoid tumors occur in the GI tract, the most common sites
being the small bowel (38%), appendix (18%) and rectum (21%). They can either be
sporadic or occur as part of familial syndromes (0-85%) such as multiple endocrine
neoplasia I and II (MEN), Von Hippel Lindau syndrome (VHL) and neurofibromatosis
(NF).39, 40
APCs are the most frequent neoplasms of the appendix, comprising 32–57% of all
appendiceal tumors, although this fraction seems to have decreased over time from 31.8%
in the period 1973–1979 to only 12% in 1990–1997.2,

41, 42

These usually small,

apparently benign lesions are often discovered as an incidental finding during surgery.
The great majority are no larger than a pea, and it is extremely rare for them to exceed the
diameter of a quarter.31 Identification of the lesion occurs in 5 or 6 per 1000
appendectomies but an exact incidence is unknown because many lesions remain
asymptomatic.42 An autopsy series of 16,294 cases between 1958 and 1969 identified
APCs in 0.04% of individuals.43 This translates to prevalence rates of 8.4 per 100 000
population per year.43 The comprehensive analysis of the Surveillance, Epidemiology and
End Results program of the National Cancer Institute (SEER), however, recorded 4.48
cases per 100 000 population per year.29 This possibly implies that a considerable
percentage of carcinoid lesions remain asymptomatic and undetected throughout the life
span of a patient. Reported epidemiology may therefore reflect more a change in
diagnostic and therapeutic behavior than a real change in prevalence of the disease
itself.29 The true number is assumed to be much higher because the use of
immunocytochemistry in the detection of NE tumors is a relatively recent development.
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Though previously recognized as the most frequently occurring of carcinoid
tumors, the relative frequency of appendiceal tumors appears to have decreased over time
(4.7% of all carcinoid tumors and 18% of all GI carcinoids [Figure 2].44

Figure 2. Distribution and 5 Year Survival Rates of Gastrointestinal Carcinoid Tumors

Possible contribution to this relative decrease in incidence has been the
widespread use of endoscopy, ultrasonography, computerized tomography, MRI, and
somatostatin receptor scintigraphy (OctreoScan), which have significantly enhanced the
identification of previously undetectable lesions in locations that are not explored as
routinely and readily as the appendix.45 As a consequence, carcinoid tumors of the gut
“appear” to have increased in incidence over the last 20 years.44 Additionally, the overall
incidence of primary appendectomy decreased by approximately 20%,with consequently
fewer APCs being detected.45
The persisting impression that the appendix is the most common site might have
arisen from the fact that removal of the appendix is one of the most frequently performed
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operations, as there is almost no other organ in the human body which is more often
available for histopathological examination, either following surgical removal for signs
and symptoms of acute appendicitis or following exploration during pelvic procedures
performed in women, which is probably even more extended by the introduction of
laparoscopy facilitating this type of invasive diagnostic intervention.44,29 Consequently,
several studies reported a preference for female gender (over 80%).38, 46 Although this
pattern has decreased from 77% to 57% in the latest SEER data analysis.44, 47
In addition, APCs present in a younger patient population than other GI carcinoid
tumors, with a median age of 49.3 years, which probably reflects the role of
appendectomy in the identification of such lesions.44 When they are found in the elderly,
they are frequently calcified, with only a few remnant tumor cells.31 Of note, those with
larger tumors and metastases are usually younger (29 years of age) than those with
smaller and clinically “benign” lesions (42 years of age).48

4. Clinical Features
As was already suggested, many APCs are asymptomatic, found incidentally and
diagnosed only by post surgery histopathological examination [Table 1].

Table 1. Frequency of symptoms in gastrointestinal carcinoids
Abbreviations: aqua 1+: rare (<10%); yellow 2+: modest (11-50%); red 3+: frequent (>50%)
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Nonspecific abdominal pain in the lower right abdomen frequently leads to
appendectomy, with some broadening of the appendix tip detected on surgery.4 More
aggressive goblet-cell carcinoids often present with a diffusely inflamed appendix.29
Although some radiologists recommend CT scanning whenever an appendiceal mass is
suspected, routine application of this technique is not likely to really increase the
preoperative diagnosis of this rare entity. Additionally, improvement in preoperative
imaging is unlikely due to the similarity of NETs to inflammation, and therapeutic
decision-making would not be altered. The same is true for ultrasound, which because of
its universal availability and non-invasiveness has become a useful tool in the diagnosis
of appendicitis. However, the differential diagnosis of a small (<1 cm) APC compared to
a local inflammation process is still a very distant hope.
Systemic manifestations of carcinoid disease include flushing, sweating, diarrhea,
or bronchospasm, are often paroxysmal and are the result of the secretion of bioactive
substances by either the primary lesion or metastases. However, carcinoid syndrome is
rare and requires abundant disease or liver metastases.49,50 In addition, cardiac failure
may occur as a result of tricuspid or pulmonary valvular fibrosis.
As for other gastrointestinal NETs, a significant number (7 to 48%) of coexistent
malignant tumors can be found, primarily throughout the gastrointestinal tract, which is
the reason why patients with proven appendiceal NET should undergo total colonoscopy
and have a complete diagnostic workup.29Of note is the yet to be elucidated association
of APCs with Crohn's disease. Small appendiceal NETs (<1 cm) have an excellent
prognosis after appendectomy specimens of Crohn's patients revealed an incidence of 0.3
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carcinoids, exceeding the reported rates of detection of these lesions after removal of the
appendix for appendicitis or the rate of APCs in autopsy studies.51

5. Clinical relevance
Keeping in mind that carcinoid may be the final pathological diagnosis in approximately
one in 300 patients undergoing appendectomy, every surgeon has a considerable
probability of facing this tumor type.48 Realizing an average appendectomy rate of 100
operations per year in a community hospital, APC remains a persistent problem featuring
approximately one or two cases a year per hospital. Although APCs have the best
prognosis among all types of carcinoids [Figure 1], this primarily reflects the anatomic
location and easy availability for exploration, which leads to early detection and removal.
5. a. Classic determinants of malignancy
5. a. i. Tumor size
As for most tumors, risk of metastases is associated with tumor size. Although early
reports indicate that 4.6% of APC present metastatically on diagnosis, this number is
much less than the 38.8% of the late SEER series.44, 48 However, the criteria for NET
registration in this surveillance program changed over time. Namely, while the early
series collected data on miscellaneous ‘carcinoid’ tumors of the appendix, the late
registration collected data only on NETs specifically classified as ‘malignant
carcinoids’.38
The risk of metastases in lesions <1 cm is virtually zero.29 The tumors between 1
and 2 cm are metastasized in 0–1%. Lesions larger than 2 cm, however, are non-localized
in 20–85%.47, 52, 53, 48, 54 Furthermore, 60–76% of APCs are smaller than 1 cm, 4–27% are
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1–2 cm, and 2–17% are larger than 2 cm in diameter.55 In the Mayo Clinic series 21% of
APCs 2–3 cm and 44% of lesions >3 cm were metastasized at diagnosis, but no tumor
measuring <2 cm exhibited metastatic spread. 48
5. a. ii. Tumor invasion
In addition to tumor size, the metastatic potential depends greatly on the depth of
penetration and the site of origin.56 Thus, mesoappendiceal invasion occurs more
frequently in patients with distant and lymph node metastases and should be used as a
determinant in indicating the need for right hemicolectomy.57 Some reports, however,
have suggested that the invasion of the mesoappendix is not a reliable predictor of
metastatic potential.54, 58 Serosal involvement is demonstrated to be present in about 70%
of all malignant NETs, but is deemed to be unrelated to outcome in the published
literature.29 Contradictory data are given for vascular invasion, which in some studies is
not significantly related to outcome, whereas it is regarded as a feature of elevated
malignant potential in others.4
Five-year survival rates for localized lesions, regional spread, and distant
metastases are 80.8%, 88.1%, and 9.6%, respectively, with an overall survival rate of
71% [Figure 3].44
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Figure 3. Five Year Survival.
Loc – lesion described as in situ of confined to organ of origin;
Reg – local invasion or lymph node metastasis;
Met – evidence of metastatic invasion of other organs;

The overall 5-year survival rate is among the best of all types of carcinoids and
reflects both the early and often serendipitous detection of the tumor as well as, in most
cases, the modest biological behavior of the lesions.

4, 33, 44

These data do not, however,

differentiate tumors into specific subtypes such as high- or low-grade GBC. For instance,
the survival of patients with mucinous variants is far less propitious and is estimated
overall to be ~26±19 months.59
5. a. iii. Tumor histology
To optimize phenotypic assessment and optimize therapeutics of gastrointestinal NE
tumors, a comprehensive classification has been proposed [Table 2 ].14
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Table 2. Criteria for prognosis assessment of gastrointestinal NETs.
*Exception: benign NETs of the appendix usually invade the muscularis propria; WD – well-differentiated;
PD – poorly differentiated

In addition to physical properties of individual lesions (size, invasion), the
presently available tools for tumor evaluation also rely on the antigenic asset of NE cells
and the tumor classification criteria.14 The former comprises molecules of the endocrine
cell machinery found in the cytosol (NSE) or in the secretory vesicles (CgA in large
dense core vesicles and synaptophysin in synaptic-like microvesicles). These antigens are
common to all NE cell types, while the hormonal content of secretory granules identifies
a specific cell type. The latter consist of morphologic/biologic criteria including tumor
size, angio-invasion, proliferative activity, histologic differentiation, metastases, invasion,
and hormonal activity (association with clinical syndromes or diseases). Since their
highly aggressive cancer-like course, the neoplasms classified by the WHO as poorly
differentiated endocrine carcinomas, with high-grade malignant behavior, are profoundly
different as compared to well-differentiated lesions and require an aggressive therapeutic
approach.14
A combination of these findings has given shape to present surgical management
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guidelines of APCs. Typically, lesions >2 cm in diameter are seen to benefit from an
oncological resection of the right hemicolon. Small appendiceal NETs (<1 cm) have an
excellent prognosis after appendectomy. Although the decision may be clear-cut for
APCs <1 and >2 cm, the intermediate type has a small but detectable risk of metastasis
and needs further evaluation. In principle, hemicolectomy is suggested in APCs 1–2 cm
in size if the mesoappendix and angioinvasion are demonstrable, a high proliferative
index and Ki67 level is apparent, and lesions are located at the base of the appendix with
positive margins.29
Despite numerous contributions to the elucidation of the histologic, pathologic,
and biochemical characteristics of GEP-NETs, including APCs, currently, there is no
reliable means of predicting the malignancy and metastatic potential of these tumors.5
Thus, it is apparent that the delineation of the molecular basis of such tumors is required
to define tumor characterization, facilitate diagnosis, rationalize therapy, and establish
prognosis.
5. b. Biological Determinants of Malignancy
To date, optimal surgical strategies for APC tumors have been inferred from the
retrospective analysis of surgical and pathological series and are based on a variety of
criteria including, but not limited to - tumor size, mitotic index, meso-appendiceal
invasion, lymph node spread, and location of the lesion.4, 60, 61 Nevertheless, recurrences
of these tumors or pseudomyxoma peritonei occur. The failure to accurately define the
biology of the tumor or precisely predict its pathological behavior play a major role in
these developments.4,

60, 61

In the future, it is likely that the definition of specific

molecular signatures will enable prediction of behavior, irrespective of size.
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Pathologic staging or grading of carcinoids includes angioinvasion and
differentiation is limited, whereas sentinel lymph node mapping is not routinely
undertaken.25 The utility of Ki-67 as a prognostic index in NE tumors has been
documented, but this marker provides scant predictive information.62-64 Overall, therefore,
determinants of malignancy and metastasis are lacking, and what is known reflects the
quantification of disease extent, as opposed to delineation of the biological behavior of
the tumor. At present, no technique exists to identify whether or when a tumor is
malignant and to determine whether it has already developed, or is likely to develop,
metastases. Novel strategies for the identification of when a primary tumor becomes
metastatic are based on molecular profiling of the tumor. In the gastrointestinal tract,
methods including gene expression analyses and molecular analysis of specific genes
(e.g., p53) have been undertaken in colorectal tumors.65, 66
The relationship between the size of a tumor and its malignancy is often
coincidental, since metastasis occurs as a result of a series of well-characterized
alterations in a variety of genes that define cell adhesion, proteolysis, migration, and
angiogenesis. These regulatory genes can be identified at a molecular level and may
provide the basis for generating a molecular profile of individual tumors that can be then
used to predict behavior and thus allow for a refinement of therapeutic strategy.67
Histological analysis per se (of NE lesions especially) cannot determine if a tumor
is benign or malignant, and despite considerable progress in molecular biology,
molecular staging has yet to be integrated into current prognostic/predictive pathological
protocols.68 In the absence of this combinatorial synergistic approach, the biological basis
of APC malignancy and metastasis is unknown, unpredictable and hence it is currently
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not possible to accurately or adequately define appropriate surgical management. This is
reflected in the large SEER (NCI) database study that concluded that the most important
predictor of survival was “extent” of disease and not histology. 38
5. c. Experience with gastric and small intestinal carcinoids
Small intestinal enterochromaffin cell tumors (carcinoids) and APCs are derived from the
EC cell, although overall the former behave more aggressively than appendiceal
lesions.33 Nevertheless, both can exhibit local spread, lymph node metastasis and distant
(liver) metastases, while the appendiceal GBC variants may produce myxoma peritonei
and ovarian implantation lesions.69, 70
At this time, no molecular signature exists to differentiate between a malignant
and benign carcinoid of the appendix. Such information would be of considerable clinical
importance when appendiceal tumors are identified and the need for further surgery is
uncertain, given that current management strategies are based on relatively simplistic
macroscopic criteria and light microscopy.71
Our group has identified the following candidate genes to be differentially overexpressed in a variety of gastrointestinal NE cells, including EC and ECL cells:
Chromogranin A (CgA), the mitotic regulatory gene, Nucleosome Assembly Protein 1Like 1 (NAP1L1), the adhesion gene, Melanoma Antigen D2 (MAGE-D2), the
malignancy marker gene, Metastasis-Associated Protein 1 (MTA1) and the caspase-3
activating apoptosis gene, NAcht Leucine-rich-repeat Protein 1 (NALP1).72
NAP1L1 has been demonstrated to be upregulated in hepatoblastomas compared
with nondiseased adult livers.73 MAGE-D2 has been identified as a molecular marker
predictive of colorectal liver metastases overexpressed in >75% of primary tumors with
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metastases.74 Overexpression of MTA1 mRNA and protein has been associated with
tumor invasion and metastasis in a variety of tumors, including breast, hepatocellular,
esophageal, gastric, and colorectal adenocarcinomas.75-79
In previous studies we have demonstrated that the differential expression of these
genes enables the delineation of localized non-metastatic (Type I/II) gastric carcinoids
from aggressive sporadic or NE carcinoma type tumors (Type III/IV).80 In addition, by
QRT-PCR, NAP1L1 was found to be significantly overexpressed in small intestinal
carcinoids compared with colorectal carcinomas and healthy tissue.81 Increased levels
were identified in both liver and lymph node metastases. Levels in colorectal carcinomas
were the same as in healthy mucosa. MAGE-D2 and MTA1 were increased in primary
tumors and metastases and overexpressed in carcinomas. Automated quantitative analysis
demonstrated the highest levels of MTA1 immunostaining in malignant primary small
intestinal carcinoids and in metastases to the liver and lymph nodes, which were
significantly increased compared with nonmetastatic primary tumors.

6. Hypothesis
Based upon the differential expression of these genes in gastric and small intestinal
carcinoid tumors, we hypothesize that these genes will enable discrimination
between different types of appendiceal tumors (non-malignant and those identified
incidentally at surgery during routine or acute appendectomy versus aggressive and
metastatic).
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7. Methodology
To establish and verify the clinical utility of a PCR-based protocol for the tissue resource,
we initially examined archival material. For this, we utilized paraffin-embedded tissue
and archival samples which constitute the majority of bankable tissue available for
analysis. We examined archival paraffin-embedded samples (collected between 19652004 by the Yale Department of Pathology) to evaluate the expression of the marker
genes of interest and correlated their expression with clinical data, tumor size and the
presence of clinically and histologically documented metastasis. Thereafter, we
prospectively examined gene expression in surgically collected appendiceal samples,
largely from patients with acute appendicitis, to establish the utility of this molecular
approach in readily available samples. These studies were approved by the Human
Investigations Committee at Yale University School of Medicine (HIC # 12589).
7. a. Tissue specimens:
Paraffin-embedded tumor tissue blocks were collected from twenty-five patients (M:F =
8:17; median age [range] = 40 yr [11-95]) with histologically-proven APC tumors who
had undergone surgical resection for acute appendicitis or a primary tumor between 1965
and 2004 in the Yale University Department of Surgery. Control tissue included
colorectal adenocarcinomas (n=5) and normal tissue samples from adjacent,
macroscopically normal, non-tumor mucosa (n=5) were also examined.
Appendiceal samples were prospectively collected from twelve patients (M:F =
8:4; median age [range] = 19 yr [6-38]) with acute or suppurative appendicitis (n=11)
and one histologically-proven invasive APC tumor [including mucosa (n=2); omental
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(n=3) and liver metastases (n=1)] who had undergone emergency surgical resection in
2004 at the Yale University Department of Surgery.
7. b. Tissue techniques:
RNA Isolation: Paraffin blocks were deparaffinized and digested as previously
described.82,

83

Total RNA was isolated from paraffin-blocks or frozen sections using

TRIzol reagent (Invitrogen, Carlsbad, CA) as described.84 RNA was then dissolved in
DEPC water, measured spectrophotometrically and an aliquot analyzed on a denaturing
gel using electrophoresis to check the quality of RNA isolated.
Q RT-PCR: Forty-two samples were examined by quantitative real-time PCR using the
Assays-on-Demand approach (Applied Biosystems) since this system identifies RNA of
60-150 base pairs in length and is thus particularly suitable for paraffin-tissue
examination.83 Message from CgA, NAP1L1, MAGE-D2, MTA1, NALP1 and the housekeeping gene, GAPDH, were quantitatively measured.84 Q RT-PCR was performed using
the ABI 7900 Sequence Detection System. Total RNA from each sample was reverse
transcribed using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA) following the manufacturers instructions. Quantitative real time PCR analysis was
then performed in triplicate. cDNA in 7.2 μl of water was mixed with 0.8 μl of 20 x
Assays-on-Demand primer (CgA = Hs00174938; NAP1L1 = Hs00748775, MAGE-D2 =
Hs00374760, MTA1 = Hs00183042, NALP1 = Hs00248187, GAPDH = Hs99999905) and
probe mix, 8 μl of 2x TAQMAN Universal Master mix in a 384 well optical reaction plate.
The following PCR conditions were used: 50°C for 2 min, then 95°C for 10 min,
followed by 40 cycles at 95°C/0.15 min and 60°C /1 min. A standard curve was
generated for each gene using cDNA obtained by pooling equal amounts from each
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sample. The expression level of target genes was normalized to internal GAPDH. Data
was analyzed using Microsoft Excel and calculated using the relative standard curve
method (ABI, User Bulletin #2).
7. c. Immunostaining of appendicitis specimens
Triple-color immuno-staining was performed on tissue sections using monoclonal
antibodies against CgA to identify the cellular location of this marker.84, 85 For antigen
retrieval purpose, sections were initially immersed in citrate buffer (10 mm sodium
citrate, pH 6.0) and subjected to 1 x 10 min high temperature-high pressure treatment
followed by treatment with 0.3% H2O2 in methanol for 30 min at 37°C to inactivate
endogenous peroxidase. Slides were then incubated for 24 hr at 4°C with a 1:1000
dilution of the anti-CgA mouse monoclonal antibody (DAKO Corp, Carpinteria, CA) and
rabbit anti-cytokeratin antibody cocktail (AE1/AE3; DAKO Corp) (to identify tumor
carcinoid cells). Goat anti-mouse antibodies conjugated to a horseradish peroxidasedecorated dextran polymer backbone (Envision; DAKO Corp, Carpinteria, CA) were
used as a secondary reagent for CgA, and goat anti-rabbit antibodies conjugated to Alexa488 fluor (DAKO Corp) were used to identify cytokeratin. CgA staining was visualized
with a fluorescent chromogen (Cy-5-tyramide; NEN Life Science Products, Boston, MA)
and nuclei were visualized by 4’, 6-diamidino-2-phenylindole (DAPI). A pathologist
(Dr. Robert Camp, Yale Department of Pathology) examined staining expression.
7. d. Statistical analysis
Results are expressed as mean ± SEM; n indicates the numbers of patients in each study
group. Statistical significance was calculated by the two-tailed Student’s test for paired
and unpaired values as appropriate, with a probability of < 0.05 representing significance.
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Linear regression analysis was performed to evaluate the relationship between CgA levels
and tumor size.

8. Results
8. a. Clinical results
Sixteen of the 25 paraffin-embedded appendiceal tumors were carcinoids identified
incidentally post-operatively with no evidence of serosal invasion or lymph node
metastasis [Table 3].

Table 3. Clinical evaluation of 25 patients with APCs
*median values and range; LI = locally invasive, LNM = lymph node metastases,
metastases; † p = 0.053 vs. “incidental”.

LVM = liver

The mean size (±SEM) of these tumors was 0.68cm ±0.075. The mean age of
the patients at diagnosis was 36.9 years and the follow-up was 113 months. None of the
patients subsequently developed lymph node or liver metastases and were considered
disease-free. Nine of the remaining tumors presented with local invasion and liver or
lymph node metastases. Three exhibited a goblet-cell phenotype and were considered to
be appendiceal adenocarcinoids. The mean size of the nine tumors was significantly
greater than the sixteen incidentally-identified lesions (2.7cm±0.4 versus 0.7±0.08;
p<0.00002). The mean age of these patients at diagnosis was 57 years and the followup was 199 months. One patient subsequently developed liver metastases. All patients
in this group were considered disease-specific.
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The eleven fresh frozen samples had suppurative appendicitis (n=3 samples
with peri-appendicitis) with no pathological evidence of carcinoid tumor.
8. b. RNA isolation
RNA isolated from twenty-five paraffin-embedded APC tumor specimens and ten
control samples had concentrations ranging from 0.02-0.14 µg/µl. Using Assays-onDemand (Applied Biosystems), GAPDH was amplified in all samples using Q RT-PCR
[Figure 4]. These results confirm, as previously determined, that this approach is
suitable for paraffin-tissue examination.83

Figure 4: Real-time PCR plots using the Assays-on-Demand approach (Applied Biosystems) of the housekeeping gene, GAPDH, in paraffin-embedded APC tissue.
Figure 4A: Amplification plot of PCR fluorescence versus cycle number for the pooled carcinoid samples.
This demonstrates concentration-dependent amplification of GAPDH.
Figure 4B: Standard curve of GAPDH (CT values plotted versus the log of the initial amount of cDNA)
derived from 4A. The level of gene expression in a sample is calculated from the CT and standard

curve. CT = the threshold cycle.
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8. c. Quantitative real-time PCR
8. c. i. Chromogranin A:
Chromogranin A was amplified in all appendiceal tumor samples and was significantly
elevated (100→1000-fold; p<0.05) in the incidental and malignant appendices and ~50fold in the GBC adenocarcinoids compared to normal mucosa and to colorectal
adenocarcinomas [Figure 5].

Figure 5: Message levels of CgA determined by Q RT-PCR.
Levels of CgA were significantly over-expressed (~100x) in incidental (benign) APCs (AI),
malignant APCs (AM; >1000x) and APCs with GBC morphology (AGC; ~20x) as
compared to normal mucosa (AN). Malignant carcinoids also had elevated CgA levels
compared to incidental and GBC carcinoids. No differences were noted between colorectal
cancer (CRC) samples and normal mucosa (AN). (#p=0.05, *p<0.05, **p<0.01, ***p<0.005).
Mean±SEM.

Malignant tumors also had elevated CgA levels compared to incidental lesions
(98±41 vs. 1.02±0.6, p=0.048). The fact that the CgA levels of the GBC adenocarcinoids
were comparable to the serendipitously-identified lesions might be considered to reflect
NE cell number. An examination of the relationship between tumor size and CgA
message levels, however, only identified a moderate correlation between these two
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parameters (R2=0.304, p=0.063). Although it has been suggested that a relationship exists
between plasma CgA and tumor size, our data suggests that tumor size and mRNA levels
may not be as closely correlated as previously considered.86 This is consistent with other
reports indicating that cellular secretory product levels may have little relationship to
plasma values.87
8. c. ii. NAP1L1:
NAP1L1 is a nuclear protein involved in chromatin assembly and DNA replication.88
Messenger RNA levels of NAP1L1 were elevated >10-fold (p<0.03) in malignant APC
tumors and in GBC adenocarcinoids compared to normal mucosa. Levels were also
elevated >100-fold (p<0.006) in malignant carcinoids compared with the incidentally
identified lesions [Figure 6]. Levels in colorectal adenocarcinomas were not different to
normal mucosa.

Figure 6: Message levels of NAP1L1 determined by Q RT-PCR.
Levels of NAP1L1 were significantly over-expressed in malignant APCs (AM; ~15x), and in APCs with
GBC morphology (AGC; ~8x) compared to normal mucosa (AN). Malignant carcinoids also had elevated
NAP1L1 levels compared to incidentally identified carcinoids (AI). (*p=0.03, **p<0.01, #p=0.006).
Mean±SEM.
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8. c. iii. MAGE-D2:
MAGE-D2 is an adhesion gene and potential predictive marker of colorectal liver
metastases.74 Levels of MAGE-D2 were elevated 10–100-fold (p<0.01) in the malignant
APCs, GBC adenocarcinoids and colorectal adenocarcinomas compared to normal
mucosa [Figure 7]. Both malignant appendiceal tumors and colorectal tumors had
elevated expression levels of MAGE-D2 compared to incidentally identified carcinoids.
No differences in expression were noted between the latter and normal mucosa.

Figure 7. Message levels of MAGE-D2 determined by Q RT-PCR.
Levels of MAGE-D2 were significantly over-expressed in malignant APCs (AM; ~100x), in APCs with
GBC morphology (AGC; ~12x) and in colorectal cancer (CRC; ~100x) samples compared to normal
mucosa (AN). No significant differences were noted between incidental (benign) APCs (AI) or normal
mucosa. Malignant carcinoids and CRC tumors had elevated MAGE-D2 levels compared to incidental
carcinoids. (*p<0.01, #p<0.005, **p<0.001). Mean±SEM.
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8. c. iv. MTA1:
MTA1 is an estrogen-antagonistic breast cancer malignancy gene that has been used for
the identification of progressive (metastatic) disease in a range of tumors including
breast, hepatocellular, esophageal, gastric and colorectal carcinomas.75-79 Message levels
of MTA1 were elevated 20–1000-fold, (p<0.01) in the malignant APCs, GBC
adenocarcinoids and colorectal adenocarcinomas compared to normal mucosa [Figure 8].
Both malignant appendiceal tumors and colorectal tumors had elevated levels of MTA1
compared with incidental carcinoids. No differences in expression were noted between
the incidental tumors and normal mucosa.

Figure 8. Message levels of MTA1 determined by Q RT-PCR.
Levels of MTA1 were significantly over-expressed in malignant APCs (AM; ~1000x), in APCs with GBC
morphology (AGC; ~15x) and in colorectal cancer (CRC; ~1000x) samples compared to normal mucosa
(AN). No significant differences were noted between incidental (benign) APCs (AI) or normal mucosa.
Malignant carcinoids and CRC tumors had elevated MTA1 levels compared to incidental carcinoids.
(*p<0.01, #p<0.005, **p<0.001). Mean±SEM.

39
8. c. v. NALP1:
The apoptotic marker, NALP1, was over-expressed ~50–100-fold, (p<0.05) in the
incidentally-identified (“benign”) and malignant APCs compared to normal mucosa
[Figure 9]. NALP1 was significantly decreased (p<0.05) in the GBC adenocarcinoids and
colorectal adenocarcinomas compared to normal mucosa. In addition, malignant
carcinoids had significantly elevated expression compared to all other tumor types.

Figure 9. Message levels of NALP1 determined by Q RT-PCR.
Levels of NALP1 were significantly over-expressed (~100x) in incidental (benign) APCs (AI) and in
malignant APCs (AM; >1000x) compared to normal mucosa (AN). Levels were significantly decreased in
APCs with GBC morphology (AGC; ~15x) and in colorectal cancer (CRC; ~1000x) samples compared to
normal mucosa (AN). Malignant carcinoids had elevated NALP1 levels compared to incidental carcinoids,
GBC carcinoids and CRC tumors. (#p=0.05, **p=0.05, *p<0.01, ***p<0.005). Mean±SEM.
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8. d. Clinical relationship between levels of gene expression and appendiceal
disease
Two of the 25 patients included in this study were lost to follow-up; both of these patients
belonged to the cohort of 16 patients with “incidental” tumors. None of the remaining 14
patients with incidental tumors for whom follow-up information was available were
subsequently identified with lymph node or liver metastases (mean follow-up 113
months: range 8-372) [Table 1].
In the group of nine patients diagnosed with malignant tumors, one patient
developed liver metastases (mean follow-up for this group was 199 months: range 33468). The small number of patients precludes a robust statistical analysis of this data.
Pathologically, the “malignant group” tumors could be separated into tumors with
local invasion (n=3), tumors with lymph node metastases (n=5) and a tumor with a liver
metastasis (n=1). An examination of gene expression levels in these categories
demonstrated that four of the five candidate genes could be associated with lymph node
or liver metastases. Thus levels of CgA, NAP1L1, MAGE-D2 and MTA1 were ~100 fold
higher in the tumors that had pathological evidence of metastases compared to APCs that
were locally invasive. Interestingly, gene expression levels in the tumors classified as
locally invasive were not different to the 16 patients with incidental tumors suggesting a
threshold of expression may be required prior to the development of metastatic disease.
These data demonstrate that gene levels of four of the five markers are potentially
clinically significant and that there is no overlap in gene expression levels between
tumors that were classified as incidental (e.g. disease-free) and tumors classified as
malignant (e.g. disease-specific).
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8. e. Prospective Q RT-PCR Analysis of Fresh Frozen Appendices
Levels of CgA were used to determine whether any covert appendiceal tumors could be
identified in eleven prospectively collected surgical acute appendicitis cases. Levels were
compared to normal appendiceal samples and to a highly malignant appendiceal tumor
with liver and omental metastases. CgA levels were elevated in the positive controls
compared with normal mucosa (p<0.0008) and ten of the eleven appendicitis specimens
(p<0.005) [Figure 10].

Figure 10. Message levels of CgA determined by Q RT-PCR.
Levels of CgA were significantly over-expressed (~15x) in the malignant appendiceal tumor and its liver
and omental metastases (AM) compared to normal mucosa (AN). Levels were not different to normal
mucosa in ten of the acute appendicitis specimens (A?). One acute sample had elevated CgA message. z =
acute appendicitis sample with abnormally elevated CgA gene expression. (*p<0.005). Mean±SEM.

Levels of CgA were low in appendicitis samples, except for one case (acute
suppurative appendicitis with peri-appendicitis) that exhibited CgA levels at ~10x levels
present in other tissues. This was significantly (p<0.02) elevated compared to both the
normal mucosa and other appendicitis specimens. Expression levels of the other four
marker genes (MAGE-D2, NAP1L1, MTA1 and NALP1) were not elevated in this sample
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and levels were not different to expression levels in the 16 “incidental” carcinoids
(examined above). Staining of this appendiceal specimen demonstrated the presence of a
cluster of CgA-imunopositivity [Figure 11]. This was absent in samples without elevated
CgA gene expression. Based on these observations, it is plausible that one of the eleven
surgically resected appendiceal specimens is worthy of consideration to be up-graded to a
covert appendiceal tumor.

Figure 11. Expression levels of CgA determined by immunohistochemistry in a suppurative appendiceal
sample with elevated CgA transcript levels.
Tri-color imaging of this section demonstrated significant overlap between cytoplasmic CgA and
cytokeratin staining in discrete areas. These included the area adjacent to the lumen (8A) where CgApositive cells forming glandular type structures were noted and in fatty areas where individual CgA-positive
cells could be noted (8B). Yellow arrow heads identify CgA-positive cells. Blue – nuclei (DAPI), green –
cytokeratin (Alexa488) and red – CgA (Cy5). Dual CgA and cytokeratin staining (red and green) results in a
yellow color. (100 x magnification).
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9. Discussion
These data demonstrate, using a Q RT-PCR approach in paraffin-embedded tissue, that
malignant APCs, which like small intestinal carcinoids are derived from the EC cell, have
elevated expression of CgA, NAP1L1, MAGE-D2 and MTA1 compared to incidentally
identified APCs [Table 4].

Table 4. Summary of gene expression.
AI – incidental APC; AM – malignant APC; GC – goblet cell APC; CRC – colorectal carcinoma
↑- message levels elevated up to 10x compared to normal mucosa; ↑↑↑ - message levels elevated between
10x-100x; ↑↑↑ - message levels elevated >100x; ↓ - message levels decreased up to 10x; ↔ - no change

GBC adenocarcinoids, which are a mixed cell tumor type that also includes NE
cells, also expressed elevated CgA, NAP1L1, MAGE-D2 and MTA1 compared to normal
mucosa. These levels were not as elevated as in the malignant EC derived carcinoid
tumors. Incidentally identified tumors, like overt malignant carcinoids, had elevated CgA
and elevated NALP1 expression. In contrast, adenocarcinoids had significantly decreased
NALP1 expression. The difference in NALP1 expression (elevated in APCs, decreased in
GBC adenocarcinoids) provides a molecular marker to differentiate between carcinoids
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and adenocarcinoids of the appendix. NAP1L1 is the human equivalent of the yeast NAPI protein, a histone-binding factor required for the maintenance of cumulative
nucleosome formation in vivo.89 Increased expression of NAP1L1 may be related to the
progression of cell growth, because levels of both NAP1L1 mRNA and protein increase
rapidly in conjunction with the induction of cellular proliferation in a T-lymphoid cell
model.88 In genome-wide profiling, NAP1L1 has been identified to be overexpressed in
fetal liver compared with adult liver and in hepatoblastomas compared with nondiseased
adult livers.73, 90 Serological identification of antigens by recombinant expression cloning
technology, which is used to search for genes whose products elicit antibody production
in the patient, has identified NAP1L1 to be a potential serological antigen in a subset
(<5%) of breast, renal, and colorectal cancer patients, but the mRNA study results were
largely negative in these studies.91 Messenger RNA levels of NAP1L1 were elevated in
malignant APC tumors and in GBC adenocarcinoids compared to normal mucosa or
incidentally identified lesions. Levels in colorectal adenocarcinomas were not different to
normal mucosa. This confirms that NAP1L1 is a marker of appendiceal carcinoid
malignancy.
MAGE-D2 has been examined in the clinical setting

by using high-density

oligonucleotide DNA arrays and has been identified as a molecular marker to predict
liver metastases from colorectal tumors.74 It is overexpressed in >75% of primary colon
tumors with metastases. Its function is still unknown, but its similarity to troponin
indicates that it is involved in cell adhesion and increased expression is thought to
facilitate the adhesion of cancer cells to vascular epithelium.74, 92 The overexpression of
MAGE-D2 in malignant APCs, GBC adenocarcinoids demonstrates that assessment of
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this marker has utility as a component of a panel for identifying and predicting the
malignant and metastatic behavior of carcinoid tumors.
MTA1 is a component of the nucleosome remodeling and histone deacetylation
complex, which is associated with adenosine triphosphate-dependent chromatin
remodeling and histone deacetylase activity.75 Functionally, MTA1 is also involved in the
transcriptional repression of methylated DNA, and in breast tissue, MTA1 represses
estrogen receptor-mediated transcription and is therefore estrogen antagonistic.93, 94 In
breast tissue, the presence of estrogen receptors is usually associated with less aggressive
tumors.95 In vitro analysis of MTA1 expression in estrogen receptor-positive cells is
associated with increased proliferation and a more aggressive phenotype.94 MTA1 is
normally expressed at low levels in various tissues but, like the cancer testes antigens, is
more highly expressed in the testis.96 On DNA arrays, MTA1 is selectively overexpressed
in metastatic prostate cancer compared with clinically localized prostate cancer and
benign prostate tissue.97 In a prostate cancer TMA, a strong relationship between MTA1
expression and prostate cancer progression has been identified.97 The close correlation
between mRNA and protein levels of MTA1 and the utility of this marker to identify
progressive disease in a range of tumors indicate that this marker will be useful in
identifying and predicting the metastatic behavior of carcinoid tumors. Both malignant
appendiceal tumors and colorectal tumors had elevated levels of MTA1 compared with
incidental carcinoids. No differences in expression were noted between the incidental
tumors and normal mucosa. This confirms that MTA1 is a marker of carcinoid tumor
metastasis.
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Previous studies have not identified specific genetic differences in EC cellderived appendiceal tumors compared to other appendiceal tumors or to normal mucosa.
In one study, no mutations were identified in K-ras, β-catenin, or DPC4 in GBC
carcinoids and p53 was not elevated, while another study determined that mucinous and
non mucinous carcinomas of appendix had similar genetic alterations.59,98 The current
study, which uses a defined panel of biologically-relevant marker genes, can distinguish
different NE tumor types found in the appendix.
The clinical relevance of this strategy is highlighted by the observation that none
of the patients with low expression levels developed metastasis. Nevertheless the
relatively short follow-up (113 months although follow-up in five of the 16 patients
extended >19 years), indicates that at this stage a degree of caution is necessary in
interpreting these results. Patients with high expression levels had pre-existing malignant
disease or subsequently developed metastases irrespective of the length of follow-up.
This group, however, was two decades older (p = 0.053 versus patients with incidental
tumors) than patients with incidental tumors, although the difference in age was not
statistically significant. Clearly, a prospective study with longer follow-up in appropriate
sex and age-matched patients is required to definitively evaluate the relationship between
gene expression of these markers and disease progress in APCs.
While histological examination is useful in staging appendiceal disease, it is
limited since a pattern-recognition technique is vulnerable when early cellular
transformation events are occurring and can only broadly predict biological outcome
once obvious changes are evident. The ability to identify at the molecular level gene
regulators that govern proliferation and invasion has obvious potential advantages. In this
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respect the objective quantification of gene expression levels, particularly genes with
defined biological functions is of potential considerable clinical advantage. Thus, in
patients where a carcinoid tumor of the appendix is identified and the need for further
surgical intervention is uncertain since the criteria of tumor size, location and light
microscopy are either inconsistent or provide ambiguous information, it is likely that the
determination of gene expression may offer novel predictive information of considerable
clinical relevance. Currently available information on which therapeutic strategy is based
requires the exercise of clinical judgment - a commodity both quite variable and
sometimes dubious in its application as opposed to objectively quantifiable molecular
data.
In the current study, using a molecular PCR-based approach, CgA expression was
detected in one of eleven histologically-negative fresh-frozen appendicitis samples. Light
microscopic examination of tissue sections, (4µm thickness), by a pathologist (RLC)
failed to identify a carcinoid tumor. Subsequent immunostaining of this section with anticytokeratin and anti-CgA followed by tyramide amplification of the CgA signal identified
clusters of cells both adjacent to the lumen and within appendiceal peri serosal fat. The
former appeared to have an epithelial morphology but were intensely CgA-positive. The
latter were consistent with microcarcinoids. It is possible that injury or inflammation may
be implicated in endocrine cell differentiation and that such events represent cytokine
mediated phenomena.99 Alternatively, such agents with well defined growth factor like
bio active properties may cause appendiceal endocrine cell hyperplasia. The latter
phenomenon has not been carefully examined in the appendix but is well-described in
association with chronic bronchopulmonary inflammation.100,

101

In addition chronic
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atrophic gastritis is also associated with ECL cell hyperplasia and may well reflect a
similar series of inflammation mediated events. It is note worthy that prolonged infection
and chronicity are key requirements in such circumstances. If either of these two
etiologies were responsible for the elevated CgA noted in our study, we would expect all
samples from the eleven patients with suppurative appendicitis to express elevated levels
of this marker. This was not the case. We therefore propose that the single patient with
elevated CgA message and CgA protein expression is an authentic example of a covert
appendiceal tumor detected using a molecular targeted strategy. Additional genetic
examination of this specimen, using gene expression of NAP1L1, MAGE-D2, and MTA1,
identified that levels of these markers were all within normal range. This serves to
support the opinion that this specimen was non-malignant (no expression of malignancyassociated genes) and could potentially be categorized as an incidental non-malignant
APC tumor.
This observation suggests that in acute appendiceal samples obtained at surgery,
covert carcinoid tumor not readily identifiable by standard light microscopy can be
identified using a molecular screen. Indeed, our previous demonstration that
approximately ~25% of histologically normal lymph nodes in small bowel carcinoid
resections are CgA-PCR-positive (indicative of covert metastasis) suggests that this
technique will be of similar utility in the identification of covert appendiceal NE
tumors.102 In general, the detection rate for APCs using standard histological techniques
in appendectomy samples is ~1%.42 Our study, using a more sensitive PCR molecular
genetic approach, suggests that this may well be higher.

49
RNA isolation from paraffin-blocks is becoming an acceptable method for
examining gene expression. In the current study, RNA was isolated from all samples and
the genes of interest were readily amplified. This confirms the utility of this technique in
APC samples as has been previously demonstrated for other tumor types and tissue
samples including Barrett’s esophageal adenocarcinomas and breast tumors.82,

83, 103

Furthermore, CgA transcript levels from these paraffin blocks could be related to protein
expression levels identified on a tissue microarray.102 Correlating CgA transcript from the
current study with protein levels of CgA measured by AQUA in the same appendiceal
tumors demonstrated these were significantly related: R2 = 0.40, p <0.03. Absence of an
absolute correlation may represent a degree of RNA degradation but is more likely to be
due to differential processing of transcript.104

10. Summary
Carcinoid tumors of the gastrointestinal tract are relatively rare compared with their
adenocarcinomatous counterparts. Nevertheless, they may display similarly aggressive
behavior. Timely and accurate diagnosis is frequently absent because symptoms and
signs may be vague and nonspecific and misconstrued as irritable bowel syndrome,
asthma, or perimenopausal symptoms or part of an anxiety or food allergy response.
Importantly, the “classical” carcinoid syndrome is expressed in relatively few instances.
Because each lesion is composed of its own distinct NE cell(s), depending on the organ
of origin, each tumor behaves as a different biological entity that requires a site-specific
therapeutic approach. However, common to all carcinoid tumors is the high percentage of
coexisting noncarcinoid tumors and multicentricity, warranting a meticulous evaluation

50
during diagnosis and treatment. To facilitate improvements in diagnosis and therapy, it is
imperative to elucidate the NE cell type involved in tumorigenesis, define their growth
regulation, characterize their secretory products, and establish the molecular basis of the
individual tumors. The need to define a plasma or genetic marker to predict or diagnose
early lesions is paramount.
Our data demonstrate over-expression of CgA and NALP1 in APCs, overexpression of NAP1L1, MAGE-D2 and MTA1 in malignant APCs and mixed cell (GBC)
adenocarcinoids, and decreased expression of NALP1 in the latter tumor type. We
therefore propose that this evaluation supports the utility of the measurement of such biomarkers to differentiate appendiceal tumor types both in paraffin-embedded and fresh
frozen samples. The ability to identify occult carcinoid tissue by CgA expression with
such amplified sensitivity also indicates that this technique may have application in the
detection of appendiceal tumors or their metastasis that cannot be identified by
conventional pathological techniques. The implications for altering staging and hence
therapeutic strategy are of clear clinical relevance.
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